Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2016 - 2022)

Historic Current Deferred Revenue for Agios Pharmaceuticals (AGIO) over the last 10 years, with Q1 2022 value amounting to $2.5 million.

  • Agios Pharmaceuticals' Current Deferred Revenue changed N/A to $2.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $61.5 million for FY2019, which is 3351.31% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Current Deferred Revenue of $2.5 million as of Q1 2022.
  • Agios Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $92.5 million during Q4 2018, with a 5-year trough of $2.5 million in Q1 2022.
  • Over the past 4 years, Agios Pharmaceuticals' median Current Deferred Revenue value was $30.7 million (recorded in 2018), while the average stood at $34.1 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 14448.76% in 2018, then crashed by 7858.08% in 2020.
  • Quarter analysis of 4 years shows Agios Pharmaceuticals' Current Deferred Revenue stood at $92.5 million in 2018, then crashed by 33.51% to $61.5 million in 2019, then tumbled by 92.28% to $4.7 million in 2020, then crashed by 47.35% to $2.5 million in 2022.
  • Its Current Deferred Revenue was $2.5 million in Q1 2022, compared to $4.7 million in Q1 2020 and $61.5 million in Q4 2019.